AQR Capital Management LLC Sells 15,915 Shares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB)

AQR Capital Management LLC decreased its stake in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) by 42.1% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 21,926 shares of the company’s stock after selling 15,915 shares during the period. AQR Capital Management LLC’s holdings in Y-mAbs Therapeutics were worth $265,000 at the end of the most recent quarter.

Other hedge funds also recently modified their holdings of the company. Squarepoint Ops LLC grew its stake in shares of Y-mAbs Therapeutics by 143.4% in the second quarter. Squarepoint Ops LLC now owns 126,389 shares of the company’s stock valued at $1,527,000 after buying an additional 74,452 shares in the last quarter. XTX Topco Ltd acquired a new stake in Y-mAbs Therapeutics in the second quarter valued at $297,000. Dimensional Fund Advisors LP grew its position in shares of Y-mAbs Therapeutics by 15.7% in the 2nd quarter. Dimensional Fund Advisors LP now owns 484,431 shares of the company’s stock valued at $5,853,000 after acquiring an additional 65,732 shares during the period. Massachusetts Financial Services Co. MA increased its stake in shares of Y-mAbs Therapeutics by 3.5% during the 2nd quarter. Massachusetts Financial Services Co. MA now owns 82,202 shares of the company’s stock worth $993,000 after purchasing an additional 2,760 shares during the last quarter. Finally, Rice Hall James & Associates LLC increased its stake in shares of Y-mAbs Therapeutics by 4.2% during the 2nd quarter. Rice Hall James & Associates LLC now owns 89,735 shares of the company’s stock worth $1,084,000 after purchasing an additional 3,589 shares during the last quarter. Institutional investors own 70.85% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts recently commented on YMAB shares. Morgan Stanley reduced their price target on Y-mAbs Therapeutics from $12.00 to $11.00 and set an “underweight” rating for the company in a report on Tuesday, August 13th. BMO Capital Markets decreased their target price on Y-mAbs Therapeutics from $26.00 to $25.00 and set an “outperform” rating on the stock in a report on Tuesday, August 13th. Wedbush reaffirmed an “outperform” rating and set a $23.00 price target on shares of Y-mAbs Therapeutics in a report on Tuesday, September 10th. Cantor Fitzgerald restated an “overweight” rating and set a $20.00 price objective on shares of Y-mAbs Therapeutics in a research report on Monday, September 9th. Finally, HC Wainwright restated a “buy” rating and set a $22.00 price objective on shares of Y-mAbs Therapeutics in a report on Tuesday, August 13th. One investment analyst has rated the stock with a sell rating, six have given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $21.14.

Y-mAbs Therapeutics Stock Down 3.5 %

Shares of Y-mAbs Therapeutics stock opened at $14.20 on Friday. The stock has a market capitalization of $623.14 million, a price-to-earnings ratio of -28.98 and a beta of 0.70. Y-mAbs Therapeutics, Inc. has a twelve month low of $4.69 and a twelve month high of $20.90. The company has a 50-day simple moving average of $13.53 and a two-hundred day simple moving average of $13.16.

Y-mAbs Therapeutics (NASDAQ:YMAB) last released its quarterly earnings results on Monday, August 12th. The company reported ($0.21) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.08). Y-mAbs Therapeutics had a negative net margin of 28.44% and a negative return on equity of 24.88%. The business had revenue of $22.80 million during the quarter, compared to analyst estimates of $23.09 million. During the same quarter in the previous year, the firm posted ($0.14) earnings per share. On average, sell-side analysts anticipate that Y-mAbs Therapeutics, Inc. will post -0.6 earnings per share for the current fiscal year.

Insider Transactions at Y-mAbs Therapeutics

In other news, insider Thomas Gad sold 30,000 shares of the business’s stock in a transaction that occurred on Monday, September 16th. The shares were sold at an average price of $12.97, for a total value of $389,100.00. Following the completion of the transaction, the insider now directly owns 67,681 shares in the company, valued at approximately $877,822.57. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In related news, insider Thomas Gad sold 30,000 shares of the firm’s stock in a transaction dated Monday, September 16th. The stock was sold at an average price of $12.97, for a total value of $389,100.00. Following the sale, the insider now directly owns 67,681 shares of the company’s stock, valued at $877,822.57. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, COO Joris Wilms sold 5,000 shares of Y-mAbs Therapeutics stock in a transaction dated Monday, August 26th. The shares were sold at an average price of $14.69, for a total value of $73,450.00. Following the completion of the transaction, the chief operating officer now owns 30,600 shares in the company, valued at approximately $449,514. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 100,000 shares of company stock valued at $1,338,100. 21.50% of the stock is owned by corporate insiders.

About Y-mAbs Therapeutics

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.